DDrare: Database of Drug Development for Rare Diseases

Searched query = "Atypical hemolytic uremic syndrome", "aHUS"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = ALN-CC5; ALXN1210; Anti-C5 antibody; CCX168; COVERSIN; Cemdisiran; Coversin; ECULIZUMAB; Eculizumab; Fc- and CDR-modified humanised monoclonal antibody against C5; IgG2/4?; MASP-2 antibody; OMS00620646, OMS620646, MASP-2 Antibody; OMS721; OMS721 100 mg/ml Injection solution, OMS00620646, OMS620646, MASP-2 Antibody; OMS721 185 mg/ml Injection solution, OMS00620646, OMS620646, MASP-2 Antibody; OMS721 Drug Product 185 mg/mL; Other: Eculizumab; RVA576; RVA576 (COVERSIN); RVA576 (Coversin); Ravulizumab; SOLIRIS; SOLIRIS - 300 MG CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO 1 FLACONCINO (VETRO) 30 ML (10 MG/ML); SOLIRIS 300 mg concentrado para solución para perfusión; Solaris; Soliris

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02614898 (ClinicalTrials.gov)	November 4, 2015	24/11/2015	Evaluation of Potential Predictors of Disease Progression in Participants With Atypical Hemolytic Uremic Syndrome (aHUS) Including Genetics, Biomarkers, and Treatment	Evidence - Evaluation of Potential Predictors of Disease Progression in Patients With aHUS, Including Genetics, Biomarkers and Treatment	Atypical Hemolytic Uremic Syndrome	Other: Eculizumab	Alexion Pharmaceuticals	NULL	Terminated	N/A	N/A	All	67		United States;Australia;Germany;United Kingdom

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT02614898
(ClinicalTrials.gov)

November 4, 2015

24/11/2015

Evaluation of Potential Predictors of Disease Progression in Participants With Atypical Hemolytic Uremic Syndrome (aHUS) Including Genetics, Biomarkers, and Treatment

Evidence - Evaluation of Potential Predictors of Disease Progression in Patients With aHUS, Including Genetics, Biomarkers and Treatment

Atypical Hemolytic Uremic Syndrome

Other: Eculizumab

Alexion Pharmaceuticals

NULL

Terminated

N/A

All

United States;Australia;Germany;United Kingdom